Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 juin 2022 04h05 HE | Source: Arbutus Biopharma Corporation

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after...
06 juin 2022 07h30 HE | Source: Arbutus Biopharma Corporation

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
14 déc. 2021 07h30 HE | Source: Arbutus Biopharma Corporation

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has...
13 déc. 2021 07h30 HE | Source: Arbutus Biopharma Corporation

Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan

Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong...
01 déc. 2021 11h58 HE | Source: Arbutus Biopharma Corporation

Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity

WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
01 nov. 2021 16h05 HE | Source: Arbutus Biopharma Corporation

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
07 juil. 2021 07h00 HE | Source: Arbutus Biopharma Corporation

Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent

Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic...

keyboard_arrow_left Page précédente